Publications by authors named "Sidarrth Prasad"
Introduction: Preeclampsia and eclampsia are hypertensive disorders of pregnancy associated with significant maternal and fetal morbidity and mortality. Posterior reversible encephalopathy syndrome (PRES) is a neurological complication observed in these conditions, yet its impact on fetomaternal outcomes remains underexplored. The aim of this study is to investigate the association between PRES and fetomaternal outcomes in women with preeclampsia and eclampsia.
View Article and Find Full Text PDFArticle Synopsis
- - Hypertensive disorders of pregnancy, particularly pre-eclampsia (PE), are major health risks for mothers and babies, with varying prevalence in places like India and significant long-term health implications for women.
- - This clinical trial explores the effectiveness and safety of two aspirin doses (75 mg vs 150 mg) in preventing preterm pre-eclampsia in high-risk women, enrolling 370 participants who will take the medication until 37 weeks of pregnancy.
- - The findings aim to optimize aspirin use for prevention, contribute to evidence-based guidelines, and assess both maternal and fetal health outcomes, potentially improving clinical practices surrounding pregnancy care.
Background: Tenecteplase (TNK) is considered a promising option for the treatment of acute ischemic stroke (AIS) with the potential to decrease door-to-needle times (DTN). This study investigates DTN metrics and trends after transition to tenecteplase.
Methods: The Lone Star Stroke (LSS) Research Consortium TNK registry incorporated data from three Texas hospitals that transitioned to TNK.
Multicenter exploration of tenecteplase transition factors: A quantitative analysis.
J Stroke Cerebrovasc Dis
April 2024
Background: Tenecteplase (TNK) is gaining recognition as a novel therapy for acute ischemic stroke (AIS). Despite TNK offering a longer half-life, time and cost saving benefits and comparable treatment and safety profiles to Alteplase (ALT), the adoption of TNK as a treatment for AIS presents challenges for hospital systems.
Objective: Identify barriers and facilitators of TNK implementation at acute care hospitals in Texas.
Background: Tenecteplase (TNK) is emerging as an alternative to alteplase (ALT) for thrombolytic treatment of acute ischemic stroke (AIS). Compared to ALT, TNK has a longer half-life, shorter administration time, lower cost, and similarly high efficacy in treating large vessel occlusion. Nevertheless, there are barriers to adopting TNK as a treatment for AIS.
View Article and Find Full Text PDF